[{"address1": "3160 Porter Drive", "address2": "Suite 250", "city": "Palo Alto", "state": "CA", "zip": "94304", "country": "United States", "phone": "650 391 9740", "website": "https://bridgebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.", "fullTimeEmployees": 550, "companyOfficers": [{"maxAge": 1, "name": "Dr. Neil  Kumar Ph.D.", "age": 44, "title": "Co-Founder, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1534840, "exercisedValue": 0, "unexercisedValue": 51135260}, {"maxAge": 1, "name": "Dr. Charles J. Homcy M.D.", "age": 75, "title": "Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 563200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank P. McCormick Ph.D.", "age": 73, "title": "Co-Founder, Chairman of Oncology & Director", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 542778, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brian C. Stephenson C.F.A., Ph.D.", "age": 42, "title": "CFO & Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1151240, "exercisedValue": 0, "unexercisedValue": 16193392}, {"maxAge": 1, "name": "Dr. Richard H. Scheller Ph.D.", "age": 70, "title": "Chairman of Research & Development", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 509622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas  Trimarchi Ph.D.", "title": "President & COO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uma  Sinha Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1313457, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Grace  Rauh", "title": "Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eli M. Wallace Ph.D.", "age": 56, "title": "Chief Scientific Officer of Oncology", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric Michael David J.D., M.D., Ph.D.", "age": 51, "title": "Chief Executive Officer of Gene Therapy", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 9, "compensationRisk": 7, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.38, "open": 25.65, "dayLow": 25.62, "dayHigh": 26.78, "regularMarketPreviousClose": 25.38, "regularMarketOpen": 25.65, "regularMarketDayLow": 25.62, "regularMarketDayHigh": 26.78, "beta": 1.075, "forwardPE": -8.664474, "volume": 1837196, "regularMarketVolume": 1837196, "averageVolume": 1936960, "averageVolume10days": 1876780, "averageDailyVolume10Day": 1876780, "bid": 26.31, "ask": 26.34, "bidSize": 100, "askSize": 100, "marketCap": 4952788992, "fiftyTwoWeekLow": 21.62, "fiftyTwoWeekHigh": 44.32, "priceToSalesTrailing12Months": 22.602676, "fiftyDayAverage": 25.903, "twoHundredDayAverage": 28.966225, "currency": "USD", "enterpriseValue": 6064612864, "profitMargins": -2.07106, "floatShares": 127525683, "sharesOutstanding": 188032992, "sharesShort": 18628832, "sharesShortPriorMonth": 17710049, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0991, "heldPercentInsiders": 0.054279998, "heldPercentInstitutions": 0.93105006, "shortRatio": 6.34, "shortPercentOfFloat": 0.1525, "impliedSharesOutstanding": 188032992, "bookValue": -5.812, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -453819008, "trailingEps": -2.64, "forwardEps": -3.04, "pegRatio": -0.51, "enterpriseToRevenue": 27.677, "enterpriseToEbitda": -12.212, "52WeekChange": 0.02836299, "SandP52WeekChange": 0.3593408, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BBIO", "underlyingSymbol": "BBIO", "shortName": "BridgeBio Pharma, Inc.", "longName": "BridgeBio Pharma, Inc.", "firstTradeDateEpochUtc": 1561642200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d3adccf0-6693-305c-9651-8da79033d61c", "messageBoardId": "finmb_412911458", "gmtOffSetMilliseconds": -14400000, "currentPrice": 26.34, "targetHighPrice": 70.0, "targetLowPrice": 37.0, "targetMeanPrice": 48.07, "targetMedianPrice": 46.0, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 447771008, "totalCashPerShare": 2.381, "ebitda": -496592992, "totalDebt": 1729281024, "quickRatio": 3.337, "currentRatio": 4.586, "totalRevenue": 219124000, "revenuePerShare": 1.245, "returnOnAssets": -0.48437, "freeCashflow": -348455616, "operatingCashflow": -414879008, "revenueGrowth": 0.321, "grossMargins": 0.98907995, "ebitdaMargins": -2.2662601, "operatingMargins": -79.63469, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]